Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... three Phase 1b trials in combination with Xeloda® (capecitabine), Taxotere® (docetaxel) and Gemzar® (gemcitabine), respectively. ARRY-380 - ErbB2 selective inhibitor for ...
2009 NOV 9 ... trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. Under the terms of the agreement, Medivation will ...
2009 NOV 16 ... cancer. This study looked at whether radiation therapy and chemotherapy (docetaxel) administered before surgery is possible, safe, and, ultimately, capable of preventing ...
2009 NOV 23 ... absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside ...
2009 NOV 16 ... where anthracyclines are unsuitable, as first-line therapy in combination with docetaxel, and as a single agent in third-line therapy. It is also approved for use in combination ...
2009 NOV 16 ... of head and neck carcinoma are treated with cis-diamminedichloroplatinum (II; CDDP) or docetaxel, which are the most effective chemotherapeutic agents against squamous cell carcinomas. ...
2009 NOV 9 ... American men when compared to other racial/ethnic groups. It is generally accepted that docetaxel, the standard of care for chemotherapy of HRPC, primarily exerts tumor cell death by ...
2009 NOV 9 ... that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of...
2009 NOV 16 ... According to recent research from Camperdown, Australia, "Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-refractory ...
2009 NOV 16 ... comprised conventional irradiation and weekly chemotherapy (nedaplatin plus docetaxel). Non-responder patients were excluded from further chemotherapy and were changed to ...
2009 NOV 23 ... surgery for ovarian, primary peritoneal, or fallopian tubal cancer who received IV docetaxel 60 to 70 mg/m(2) and IP cisplatin 80 to 85 mg/m(2) on day I and IP paclitaxel 60 to 70 ...
2009 NOV 9 ... and their tumors were submitted for in vitro EDR assay to taxanes (paclitaxel or docetaxel) and platinum compounds (carboplatin or cisplatin). The rates of EDR to taxanes and ...
2009 NOV 2 ... "The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of ...
2009 NOV 16 ... patients who received chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin) in a randomised controlled trial were evaluated. The ...
2009 NOV 2 ... of the esophagus received induction chemotherapy with cisplatin 75 mg/m(2) and docetaxel (Taxotere) 75 mg/m(2) on days 1 and 22, followed by radiotherapy of 45 Gy (25 x 1.8 Gy) ...
2009 NOV 9 ... signatures for many of the single agents and combinations tested. For instance, docetaxel activity showed some dependence on the expression of drug pumps, while cisplatin ...
2009 NOV 2 ... found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC. with advanced NSCLC who progressed after prior ...
2009 NOV 9 ... Jeddah, Saudi Arabia report. "There are no published reports on the use of docetaxel for ovarian cancer in pregnancy. A 32-year-old pregnant lady underwent laparatomy at ...
2009 NOV 23 ... currently approved for the treatment of progression of CRPC is the chemotherapeutic docetaxel. New therapies are needed to specifically address the multiple mechanisms that allow ...
2009 NOV 16 ... 5 or 7 mg/kg/day) as continuous infusion on days 1-7 in combination with standard-dose docetaxel (Taxotere), Adriamycin and cyclophosphamide (TAC) on day 5 as preoperative chemotherapy ...
